Fehmi Keçe

Left Atrial Box Surface Ratio and AF-Recurrence 169 8 Table 1. Demographic and baseline characteristics between patients with and without AT/AF recurrence. All (n=706) AF/AT recurrence (n=42) No AF/AT recurrence (n=28) P value Age, years 63 ± 11 63 ± 11 63 ± 10 0.950 Male gender, n (%) 53 (76) 33 (79) 20 (71) 0.495 Body Mass Index (kg/m²) 27 ± 4 27± 4 27 ± 4 0.529 Comorbidity Hypertension, n (%) 37 (53) 22 (52) 15 (53) 0922 Hyperlipidemia, n (%) 27 (39) 20 (47) 7 (25) 0.057 Diabetes Mellitus, n (%) 6 (9) 5 (12) 1 (4) 0.390 Structural Heart Disease, n (%) 21 (30) 15 (36) 6 (21) 0.201 OSAS, n (%) 6 (9) 4 (10) 2 (7) 1.000 GFR <30, n (%) 1 (1) 1 (2) 0 (0) 1.000 Duration of AF, months 59 (41–116) 59 (36–112) 57 (43–115) 0.405 Type of AF Persistent, n (%) 39 (56) 25 (60) 14 (50) 0.432 Long-standing, n (%) 31 (44) 17(41) 14 (50) 0.432 Prior PVI, n (%) 39 (56) 26 (62) 13 (46) 0.202 Prior mitral valve surgery, n (%) 8 (11) 6(14) 2 (7) 0.462 LV ejection fraction <35 1 (1) 1 (2) 0 (0) 1.000 LA volume index (ml/m²) 46 ± 19 50 ± 22 41 ± 13 0.050 CHA 2 DS 2 -VASc 2 ± 1 2 ± 1 2 ± 1 0.697 AAD, n (%) 59 (84) 36 (85) 23 (82) 0.745 Values are reported as the mean ± standard deviation, median (interquartile range), or n (%). AAD indicates anti-arrhythmic drug; AF atrial fibrillation; LA, left atrium; eGFR, estimated glomerular filtration rate; LV, left ventricle; NOAC, novel oral anticoagulant; OSAS, obstructive sleep apnea and PVI, pulmonary vein isolation. 8.3.4 Follow-up After a median follow-up of 13 (IQR 10-17) months, 42 Patients (60%) experienced AF/ AT recurrence after a median duration of 10 months (IQR 5-14). Of these patients, 28 (67%) had recurrence of atrial fibrillation, 12 (29%) recurrence of atypical flutter/atrial tachycardia and 2 (5%) of both. In 16 (24%) patients there was improvement of their symptoms and the tachycardia improved from persistent to paroxysmal. Atrial fibrillation free survival off ADD was 40%. AF-free survival on/off AAD was higher (59%). There was no significant difference in recurrence between patients undergoing ablation with and